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Background: Serous tubal intraepithelial carcinoma (STIC) and the p53 signature in tubal mucosa have been
supported to be precursor lesions in high-grade serous carcinoma (HGSC) of the fallopian tube, ovary, and peritoneum.
It remains critical to find biomarkers for precursor lesions in order to detect HGSCs efficiently. IMP3 is an oncoprotein
that has been explored in human malignancies. No studies have specifically addressed the expression of IMP3 in
precursor or early lesions of HGSC. The main purposes of this study are to evaluate if IMP3 plays any role in the
process of pelvic serous carcinogenesis by examining its expression in HGSC precursor lesions, to examine the
relationship between IMP3 and p53 in those precursor lesions, and to check if IMP3 can be used as a biomarker for
early diagnosis.
Methods: Immunohistochemistry for IMP3 and p53 was performed and evaluated in 48 HGSCs with STIC, 62
HGSCs without STIC, and 60 benign cases as negative controls. Sections of fallopian tubes with or without STIC , as
well as cancers within the ovaries, were studied. IMP3 signature was defined as strong IMP3 cytoplasmic staining
in 10 or more consecutive benign-looking tubal epithelial cells. The relationship between IMP3 and p53 overexpression
was examined.
Results: In the 48 HGSC patients with STIC, IMP3 was positive in 46% of STIC lesions and had a similar positive rate in
the invasive components of HGSC. IMP3 was also expressed in normal appearing tubal epithelia (IMP3 signature) in 15
(31%) of 48 HGSC cases with STIC and 10 (16%) of 62 cases without STIC. In contrast, no single IMP3 signature was
found in the benign control group. Concordant expression of IMP3 and p53 signatures in the STIC group was found in
up to one-third of the cases. There were also five (10%) STIC cases with positive IMP3 and negative p53.
Conclusions: We conclude that IMP3 may be involved in the process and progression of pelvic HGSC and may serve
as a complimentary biomarker in diagnosing STIC.
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Pelvic serous cancer (PSC), including mainly high-grade
serous carcinoma (HGSC) that involves the primary sites
of the ovary, the fallopian tube, and the peritoneum, is
the most common and lethal type of müllerian malignancy,
comprising more than 70% of all malignancies from these
organs [1-3]. Effective management of this disease has been
hampered because up to 90% of HGSC in patients are* Correspondence: zhengw@email.arizona.edu
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unless otherwise stated.discovered in the advanced stages. Therefore, investigators
have emphasized the importance of understanding the
early phases of this fatal disease, such as precancerous or
intraepithelial lesions, in order to find an effective method
for early detection [4]. The accumulated studies in the past
decade have revealed that the sources of pelvic HGSCs are
mainly derived from the distal fallopian tube rather than
the ovary or the peritoneum [3,5-11]. A noninvasive car-
cinoma of the fallopian tube, designated as ‘serous tubal
intraepithelial carcinoma’ (STIC), is found in up to 60%
of pelvic HGSC patients [12]. STIC, mainly localized in
the distal tube, is considered as the morphologically iden-
tifiable precursor lesion for HGSC since the cancer cellsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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clear molecular mechanism, the cancer cells of STIC are
able to detach from the tubal mucosa and “implant” on
the ovarian and peritoneal surfaces and grow into the
status of carcinomatosis within the pelvis or abdominal
cavity. Therefore, elucidation of the early phase of pelvic
high-grade serous carcinogenesis will shed light on early
detection and cancer prevention.
Although tubal high-grade serous carcinogenesis re-
mains elucidated, alteration of TP53 is a well-known gene
that plays a key role for cancer initiation and development
[13]. This was supported by the finding of p53 signatures,
defined as intense p53 protein overexpression in the normal
looking tubal epithelia [9]. This particular stretch of the
tubal epithelia is most commonly seen in the tubal fimbria,
mainly in tubal secretory cells, and TP53 gene mutations
have been found in more than 50% of the cells with p53
signatures [9]. Because of this critical molecular change,
tubal epithelia with p53 signatures are now considered as
latent precancer for HGSC [3,14,15]. STICs, as well as inva-
sive HGSCs, have been found to harbor TP53 mutations in
over 90% of cases and the majority of them stain strongly
and diffusely with the p53 antibody [9,16]. Based on these
observations, we believe that tubal HGSC follows a step-
wise developmental model and that p53 serves as an im-
portant biomarker for those serous lesions in the entire
cancer developmental process. However, as we all know,
carcinogenesis typically involves more than a single gene.
In addition, there are some significant portions of early
serous tubal epithelial lesions that are negative for p53 im-
munostaining. Therefore, other biomarkers found in this
setting will be useful for early diagnosis.
IMP3, an oncoprotein, is a member of insulin-like growth
factor II mRNA binding proteins, also known as IGF2BP3
[17,18]. IMP3 is epigenetically silenced soon after birth,
with little or no detectable protein in normal adult
tissues [19] except in placentas and gonads [20]. Re-
expression of IMP3 is observed in a series of human
malignancies, including ovarian, endometrial, and cervical
cancers, correlating with increased risk of metastases and
decreased survival [19,21-23]. Not only overexpressed
in those invasive cancers, IMP3 has also been consid-
ered as a marker of preinvasive lesions within the cer-
vix and the endometrium [22,24]. IMP3 has also been
used as a prognostic marker for all ovarian cancer pa-
tients in our routine pathology practice, during which
IMP3 overexpression was sometimes observed in normal
appearing tubal mucosa as well as in STIC cases. Such
findings prompted us to examine the following questions:
1) whether IMP3 expression is involved in the early
process of tubal HGSC development, 2) if IMP3 can be
used as a diagnostic marker for STIC, and 3) the relation-
ship between IMP3 and p53 in the process of tubal high-
grade serous carcinogenesis.Materials and methods
Case collection
A total of 170 identified cases were pulled from path-
ology files of the University of Arizona Medical Center.
The institutional review board approved the study.
There were three groups of patients in the study: HGSC
with STIC (n = 48), where these HGSCs were classified
as tubal primary since STIC was identified in tubal fim-
briated ends; HGSC without STIC (n = 62); and the posi-
tive control, which included ovarian HGSC patients
without identifiable STIC. Pathologic examination of the
fallopian tubes revealed that 53 cases had invasive can-
cer foci in the tubal wall or paratubal soft tissue, but no
STICs were identified. All of the cancer patients had no
history or either chemotherapy or radiation therapy
prior to the surgical staging. Family history of ovarian
cancer and personal history of breast cancer were col-
lected, but BRCA mutation status was not available. In
addition to the tissue samples obtained from the above
HGSC patients, we also studied tubal tissues from a
group of patients with benign gynecologic diseases (n =
60) as negative controls. These patients had no evidence
of any malignancy and came to the hospital for total hys-
terectomies and bilateral salpingo-oophorectomy because
of leiomyomata, endometriosis, or uterine prolapse.
The ages ranged from 42 to 75 with an average age of
61.5 years.Tissue handling
All of the fallopian tube samples were handled using
SEE-FIM protocol [3,25] for those cancer patients since
this is the routine procedure in UMC. Fallopian tubes
from benign control cases were processed by embedding
all fimbriated ends similar to cancer patients with add-
itional representative 2 cross sections of the ampulla as
described previously [10].
All tissues were fixed in 10% buffered formalin and
processed routinely for paraffin embedding. Five-micron
sections for IHC were cut and placed on Super Plus slides
(Fisher Scientific, Pittsburgh, PA) before sectioning each
specimen for hematoxylin and eosin staining in order
for them to be examined microscopically for diagnostic
confirmation.Morphologic analysis
The secretory and ciliated cells within the tubal mucosa
were readily identifiable under the light microscopy. To
further confirm the cell type, we stained the tubal sec-
tions with PAX8 (marker for secretory cells) and tubulin
(marker for ciliated cells). STIC is a noninvasive carcin-
oma confined to the epithelial cells of fimbriae and is
characterized by significant cytologic atypia and/or atyp-
ical intraepithelial proliferation. The histologic diagnoses
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ously [26].
Immunohistochemical analysis
The IMP3 antibody (L523S) was provided by Dako
(Carpinteria, CA), which was a mouse monoclonal
antibody (MAb) specific for the IMP3/KOC antigen.
Immunohistochemical stains were performed on 5-um
tissue sections from representative blocks using the
purified mouse anti-IMP3 antibody and the standard
avidin-biotin-complex technique as described previ-
ously [27-29]. Representative sections of endometrial
serous carcinoma served as positive controls for the
IMP3 antibody [29]. Negative controls were performed
by replacing the primary antibody with nonimmune
IgG. All slides were reviewed independently by two in-
vestigators (YW and WZ). The percentage of neoplas-
tic cells and nonneoplastic tissues that showed dark
brown cytoplasmic staining was recorded. The inten-
sity of the IHC staining was recorded as absent, weak,
moderate, or strong. IMP3 overexpression in STIC or
PSC was defined as >10% of the stained cancer cells
with strong intensity of the cytoplasmic staining. IMP3
signature was defined as strong cytoplasmic IMP3
staining in 10 or more benign appearing tubal epithe-
lial cells. PAX8 has been considered as a müllerian epi-
thelial marker identifying tubal secretory as described
previously [10].
Immunohistochemical analysis for p53 protein expres-
sion was performed as described previously. Assessment
of immunohistochemical results for p53 was based on
distinct nuclear staining. For cancer cases, positive stain-
ing was defined by staining more than 75% of the cancer
nuclei with at least a moderate degree of staining inten-
sity. Occasional cytoplasmic p53 staining was considered
as negative.
Statistical analysis
The mean values and standard errors were calculated,
and the paired t test was used by PROC MEANS in the




This study examined IMP3 expression in the fallopian
tubes of patients from the following three groups: HGSC
with STIC, HGSC without STIC, and benign controls.
The HGSC with STIC group included 48 patients who
were identified by STIC in the fallopian tubes. Patients’
ages at surgery in this group ranged from 38 to 81 years
with an average age of 57.2 years, which was about
10 years younger than that of the HGSC without STIC
group (36 to 89 years with average of 67.1 years) (P <0.005). The clinicopathologic characteristics of the two
HGSC groups are summarized in Table 1.
IMP3 in normal looking tubal epithelia
To evaluate if IMP3 was overexpressed in normal look-
ing tubal epithelial cells, we examined IMP3 expression
in sections of the fallopian tube from the two study
groups (STIC group, n = 48, and HGSC without STIC,
n = 62) and one control group (n = 60). The benign con-
trol fallopian tubes were obtained from patients without
any gynecologic malignancy. In the benign control
group, IMP3 was found to be weakly and occasionally
moderately immunoreactive in 1 of the 60 cases in less
than 1% of the tubal epithelial cells. Immunoreactivity
for IMP3 was present mainly in secretory cells and
barely in ciliated cells (Figure 1). In contrast, IMP3 im-
munoreactivity was significantly increased in the normal
looking tubal epithelia in both study groups (see the re-
sults of IMP3 signature below).
PAX8 and p53 were also examined in the parallel sec-
tions of the fallopian tubes from the control group. Im-
munoreactivity for PAX8 was found only in secretory
cells (data not shown), consistent with our previously re-
ported studies [10,30]. The immunoreactivity for p53
was not observed in the normal fallopian tubes from pa-
tients with benign gynecologic diseases, but it was found
in the study groups (see the results of p53 signature
below).
The relationship between IMP3 and p53 signatures
IMP3 signature was defined as the criteria similar to
those of the p53 signature previously described [31]: the
presence of moderate-to-strong immunoreactivity for
IMP3 in at least 10 consecutive secretory cells in the fal-
lopian tube showing no more than moderate cytologic
atypia and no intraepithelial proliferation. There were no
IMP3 signatures found in the 60 benign control fallopian
tubal samples. However, 15 (31%) of 48 patients with
STIC and 10 (16%) of 62 cancer patients without STIC
showed IMP3 signatures, respectively. Among the total
of 25 cancer cases with IMP3 signature, nine showed
p53 signatures in the same group of the cells, eight were
located in the different regions of the tubal mucosa, and
eight were negative for p53. A total of 38 p53 signatures
were found in cancer group with 20 (53%) in the STIC
patients and 18 (47%) in the HGSC without STIC group.
No p53 signatures were found in the benign control
group. The representative pictures of IMP3 signatures in
relationship with p53 signatures are present in Figure 2
and summarized in Table 2.
IMP3 and p53 Expression in STIC
The positive IMP3 overexpression was defined as more
than 10% of the target cells showing at least moderate
Table 1 Clinicopathologic features of high-grade serous carcinoma with and without STICHGSC: high-grade serous
carcinoma; STIC: serous tubal intraepithelial carcinoma
HGSC w/ STIC (n = 48) HGSC w/o STIC (n = 62) P
No. (%) patients













Bilateral 37 52 > 0.05
Cancer size (cm) mean ± SD
Fallopian tube 0.55 ± 0.21 2.66 ± 0.72 < 0.05
Ovary 3.42 ± 0.52 4.35 ± 0.64 > 0.05
Stage
I 4 0 < 0.05
II 5 3 > 0.05
III 39 51 > 0.05
IV 0 8 < 0.05
Breast cancer history 8 7
Family history 12 12
Prophylactic BSO 5 0
^indicating the adnexal location of those invasive cancers. Among the 48 STIC patients, 3 showed STIC only without invasive component. w/: with; w/o: without.
For those cases without gross lesions in the fallopian tube, the lesion size was measured microscopically.
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was defined as more than 75% of intense nuclei staining of
the target cells [32]. Among the 48 patients with areas of
STIC we studied, we observed positive IMP3 in 22 (46%)
and p53 overexpression in 40 (83%) cases, respectively. The
positive expression of IMP3 in STIC ranged from 15% to
100% cancer cells with an average of 45.5%. Among the 22
IMP3 positive cases in STIC, 17 (77%) were positive and
five (23%) were negative for p53 staining. Within the same
48 STIC patients, eight (17%) cases showed negative ex-
pression for both IMP3 and p53. The representative pic-
tures of IMP3 and p53 for STIC and the corresponding
data are presented in Figure 3 and Table 3.
IMP3 and p53 Expression in HGSC
We further examined the expression of IMP3 and p53 in
the invasive components of HGSC in both study groups
(STIC group, n = 48, and HGSC without STIC, n = 62).Within the STIC group, the staining results for IMP3 and
p53 in the invasive cancer areas were very similar to those
found in the areas of STIC (Figure 3) with the exception
of the two cases. These two cases showed positive IMP3
and negative p53 in STIC, but they were reversed (nega-
tive IMP3 and positive p53) in the invasive component.
Interestingly, eight (20%) cases with negative expression
for both IMP3 and p53 in STIC were also negative in the
corresponding invasive areas (Table 3).
In the patients of HGSC without STIC group, the
overall staining results for these two markers were also
similar to those cancer cells in the STIC group (Figure 4).
The detailed results are presented in Table 3.
Discussion
Although IMP3 expression, which is associated with tumor
growth, progression, and unfavorable prognosis, has been
explored in a number of human malignancies, only two
Figure 1 Differential expression of IMP3 and p53 in normal tubal epithelial cells. A. H/E staining of normal epithelia of the fallopian tube.
B. P53 was occasionally positive in some normal-looking secretory cells of the fallopian tube, which typically representing wild type TP53. C. IMP3
was strongly expressed in focal area of secretory cells in the fallopian tube, barely in ciliated cells in the only one case of the benign group.
Ciliated cells could be appreciated by cilia on the left of panel A. Original magnifications: Left panel 40x, right panel 200x.
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ovarian cancers have been published. Kobel et al. demon-
strated IMP3 expression in 86% of mucinous tumors, in
about half of clear-cell and high-grade serous carcinomas,
and in 27% of endometrioid cancers [19]. Noske et al.
detected expression of IMP3 in 32 (47%) of 68 ovarian
carcinomas but did not report their findings according
to various histologic types [33]. However, no studies
have been addressed regarding the IMP3 expression inFigure 2 IMP3 and p53 signatures in tubal epithelia from a high-risk
in fimbria with strong immunoreactivity for IMP3 and p53 (40x). A closer vi
panel. Immunoreactivity for IMP3 and p53 were identified in 2 different site
majority of the IMP3 and p53 signatures were overlapped in this particularprecursor or early lesions of HGSC of either tubal or
“ovarian” origins.
In this study, we have shown that IMP3 signatures,
defined as strong positive cytoplasmic staining in more
than 10 benign appearing consecutive tubal epithelia,
were found in 15 (31%) of the 48 cases with STIC. This is
in contrast to the benign control group, which showed
no single IMP3 signature, found in 60 studied cases
(p < 0.0001). Interestingly, the tubal IMP3 signaturepatient. Photographs illustrated examples of normal-looking epithelia
ew of the IMP3 and p53 signatures was shown in inserts (200x) of the
s indicated by red arrows in the same fallopian tube. Apparently, the
stretch of the tubal epithelia.
Table 2 The relationship between IMP3 and p53 signatures^ in tubal epithelia
Case group (No.) # IMP3 signatures (%) # p53 signatures (%) # Conc (%) # Discord (%) # Indep (%)
Benign (60) 0 0
w/STIC (48) 15 (31) 20 (53) 5(33) 4(27) 6(40)
w/oSTIC(62) 10 (16) 18 (47) 4(40) 4(40) 2(20)
^IMP3 or p53 signature is defined by either moderate or strong immunostainings in benign appearing tubal epithelia. Compared to the benign and cancer cases
without STIC, the number of IMP3 signature was significantly higher in the tubal epithelia of the cases with STIC with p values of < 0.0001 and < 0.05, respectively.
#Conc: the number of concordance; #Discord: the number of discordance; #Indep: the number of independent signatures of IMP3 and p53. STIC: serous tubal
intraepithelial carcinoma. w/: with; w/o: without. The concordance, discordance, and independent rate were calculated from the IMP3 signature data after
comparing the cases with p53 signature. The reverse relationship was not evaluated in this study.
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the 62 cancer cases without STIC (p < 0.05). Additionally,
concordance expression of IMP3 and p53 signatures in
the STIC group was found in up to one-third of the cases,
while the remaining was either discordant or independent
(Table 2). Overall, our findings suggest that IMP3 aberra-
tion may play a different role than TP53 in the initial
phase of tubal serous carcinogenesis.
Another important finding of this study is that IMP3
overexpression was frequently expressed (46%) in patients
with STIC who had invasive HGSC in the ovary. Al-
though this positive rate is less than the p53 positivityFigure 3 IMP3 and p53 overexpression in serous tubal intraepithelial
(mid panel) and IMP3 (low panel). Apparently, this case showed more intra
However, some of the neoplastic cells were positive for both p53 and IMP3
panel, 40x; right panel, 200x.(83%) in the same group of cases, the concordant posi-
tive staining for both IMP3 and p53 biomarkers was
found in 35% of the STIC cases. More interestingly,
there were five (10%) STIC cases showing positive
IMP3 staining but were negative for p53 overexpres-
sion. These findings suggest that IMP3 staining may aid
the diagnosis of STIC, particularly in those cases with
negative p53 staining.
Although the majority of HGSC in the pelvis is currently
classified into tubal primary, particularly when STIC is
present [3,7,34], the cancers mainly involving the ovary but
without STIC are, by convention, still classified as ovariancarcinoma (STIC). STIC (top panel) was strongly positive for both p53
epithelial cancer cells were positive for p53 than those of IMP3.
(right side of the mid and low panels). Original magnifications: left
Table 3 IMP3 and p53 immunoreactivity in STIC and invasive HGSC
Invasive HGSC of ovary
STIC W/ STIC W/O STIC
No. (%) cases P No. (%) cases P No. (%) cases P
IMP3+ 22 (46) 20 (42) 25 (40)
IMP3- 26 (54) 0.82 28 (58) 0.56 37 (60) 0.71
p53+ 40 (83) 42 (88) 53 (85)
p53- 8 (17) < 0.01 6 (12) < 0.01 9 (15) < 0.01
IMP3+/p53+ 17 (35) 17 (35) 19 (31)
IMP3+/p53- 5 (10) <0.05 3 (6) <0.05 7 (11) <0.05
IMP3-/p53+ 18 (38) 20 (42) 28 (45)
IMP3-/p53- 8 (17) 0.26 8 (17) 0.16 9 (15) 0.08
Note: The total number of patients with STIC (serous tubal intraepithelial carcinoma) cases studied was 48, while the number of invasive ovarian HGSC (high-grade
serous carcinoma) without STIC was 62. The percentage of positive or negative IMP3 with the relationship to p53 staining results was calculated by the total IMP3
positive or negative cases. The p values listed in the table represented the comparisons within the same group of patients showing different status of IMP3 and/or p53.
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(Table 3) as well as similar clinicopathologic presentations
in HGSC with or without STIC supports that HGSC with-
out finding STIC is also likely arising in the fallopian tube
[3]. One of the common reasons for not finding STIC in
those ovarian HGSCs is likely due to limited tubal samples
examined under microscopy or advanced cancer growth
obliterating the tubal fimbria.Figure 4 IMP3 and p53 overexpression in invasive component of high
(top panel) showed positive for both p53 (mid panel) and IMP3 (low panelBased on the findings discussed above, we conclude that
IMP3 may involve the initial process of pelvic high-grade
serous carcinogenesis and pelvic serous cancer progres-
sion. IMP3 may serve as a complimentary biomarker to
aid the diagnosis of STIC, particularly when it is negative
for p53 immunostaining. However, since this study is
mainly on the immunostaining level, detailed molecular
mechanism studies are needed to address if tubal epithelia-grade serous carcinoma (HGSC). Example of invasive HGSC
). Original magnifications: left panel, 40x; right panel, 200x.
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and if it has a synergistic role in facilitating cancer develop-
ment with TP53. Other studies such as the risk of IMP3
signatures in cancer prediction and overexpression of IMP3
in HGSC in relation to patient survival and response to
adjuvant therapies are also pertinent in the near future.
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